DK2704711T3 - Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension - Google Patents

Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension Download PDF

Info

Publication number
DK2704711T3
DK2704711T3 DK12779354.5T DK12779354T DK2704711T3 DK 2704711 T3 DK2704711 T3 DK 2704711T3 DK 12779354 T DK12779354 T DK 12779354T DK 2704711 T3 DK2704711 T3 DK 2704711T3
Authority
DK
Denmark
Prior art keywords
treatment
arterial hypertension
pulmonal
pulmonal arterial
hypertension
Prior art date
Application number
DK12779354.5T
Other languages
Danish (da)
English (en)
Inventor
Edda Spiekerkoetter
Marlene Rabinovitch
Philip A Beachy
David Solow-Cordero
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of DK2704711T3 publication Critical patent/DK2704711T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK12779354.5T 2011-05-02 2012-04-30 Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension DK2704711T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161481317P 2011-05-02 2011-05-02
PCT/US2012/035793 WO2012151153A1 (en) 2011-05-02 2012-04-30 Use of fk506 for the treatment of pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
DK2704711T3 true DK2704711T3 (da) 2021-02-22

Family

ID=47108011

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12779354.5T DK2704711T3 (da) 2011-05-02 2012-04-30 Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension
DK20211109.2T DK3821891T3 (da) 2011-05-02 2012-04-30 Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK20211109.2T DK3821891T3 (da) 2011-05-02 2012-04-30 Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension

Country Status (19)

Country Link
US (6) US9474745B2 (enExample)
EP (3) EP4279130A3 (enExample)
JP (1) JP6177765B2 (enExample)
AU (2) AU2012250974B9 (enExample)
CA (1) CA2834368C (enExample)
CY (1) CY1123900T1 (enExample)
DK (2) DK2704711T3 (enExample)
ES (2) ES2856173T3 (enExample)
FI (1) FI3821891T3 (enExample)
HR (1) HRP20210245T1 (enExample)
HU (1) HUE053229T2 (enExample)
LT (1) LT2704711T (enExample)
PL (1) PL2704711T3 (enExample)
PT (2) PT3821891T (enExample)
RS (1) RS61480B1 (enExample)
SI (1) SI2704711T1 (enExample)
SM (1) SMT202100085T1 (enExample)
WO (1) WO2012151153A1 (enExample)
ZA (1) ZA201307905B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2704711T3 (da) 2011-05-02 2021-02-22 Univ Leland Stanford Junior Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension
AU2016207046B2 (en) * 2015-01-13 2021-04-01 Vivus Llc Combination therapy for pulmonary hypertension
MX2017014301A (es) * 2015-05-08 2018-03-23 Vivus Inc Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar.
CN108070566A (zh) * 2015-08-05 2018-05-25 中国医学科学院基础医学研究所 肺动脉高压治疗药物的干细胞筛选模型及应用
ES2683921B1 (es) * 2017-03-28 2019-04-22 Univ Vigo Método para la determinación del pronóstico en sujetos diagnosticados con hipertensión arterial pulmonar
EP3624821A4 (en) * 2017-05-19 2021-01-20 The Board of Trustees of the Leland Stanford Junior University ENZASTAURIN AND FRAGILE HISTIDINTRIAD (FHIT) - ENHANCING AGENTS FOR TREATMENT OF PULMONAL HYPERTENSION
EP3773571A1 (en) 2018-03-28 2021-02-17 Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin Prevention or treatment of chronic organ injury

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
US20050119330A1 (en) 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
FR2936060B1 (fr) * 2008-09-17 2010-11-19 Assist Publ Hopitaux De Paris Procede de diagnostic d'une sclerodermie systemique ou d'une hypertension arterielle pulmonaire.
MX2011004284A (es) * 2008-10-22 2011-06-21 Sam Amer & Co Inc Metodo para tratar la hipertension arterial pulmonar.
DK2704711T3 (da) 2011-05-02 2021-02-22 Univ Leland Stanford Junior Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension

Also Published As

Publication number Publication date
SMT202100085T1 (it) 2021-05-07
CA2834368C (en) 2020-02-18
ES2856173T3 (es) 2021-09-27
WO2012151153A1 (en) 2012-11-08
EP4279130A2 (en) 2023-11-22
LT2704711T (lt) 2021-04-26
EP2704711A4 (en) 2014-11-19
JP2014513121A (ja) 2014-05-29
HUE053229T2 (hu) 2021-06-28
US9474745B2 (en) 2016-10-25
EP3821891A1 (en) 2021-05-19
CA2834368A1 (en) 2012-11-08
HRP20210245T1 (hr) 2021-04-02
AU2012250974B2 (en) 2017-05-04
US20170007585A1 (en) 2017-01-12
ZA201307905B (en) 2015-05-27
US20180185340A1 (en) 2018-07-05
US20220184042A1 (en) 2022-06-16
CY1123900T1 (el) 2022-05-27
EP3821891B1 (en) 2023-06-07
JP6177765B2 (ja) 2017-08-09
US20140135358A1 (en) 2014-05-15
ES2954905T3 (es) 2023-11-27
US12521379B2 (en) 2026-01-13
SI2704711T1 (sl) 2021-04-30
PL2704711T3 (pl) 2021-07-05
US20230404982A1 (en) 2023-12-21
AU2017210583A1 (en) 2017-08-24
DK3821891T3 (da) 2023-09-04
FI3821891T3 (fi) 2023-08-24
AU2012250974A1 (en) 2013-11-14
AU2017210583B2 (en) 2019-02-07
PT3821891T (pt) 2023-08-31
EP2704711B1 (en) 2020-12-02
US20190091208A1 (en) 2019-03-28
AU2012250974B9 (en) 2017-05-18
RS61480B1 (sr) 2021-03-31
EP2704711A1 (en) 2014-03-12
EP4279130A3 (en) 2024-02-21
PT2704711T (pt) 2021-03-02

Similar Documents

Publication Publication Date Title
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
DK2498771T3 (da) Anvendelse af bethanechol til behandling af xerostomi
IL231228A0 (en) Bicyclic heterocycle derivatives for the treatmen t of pulmonary arterial hypertension
DK2558105T3 (da) Bardoxolonmethyl til behandling af fedme
DK2766392T3 (da) Fremgangsmåde til oprensning af antistoffer
DK3357511T3 (da) Inhibitorer af t-celleaktivering
DK2768857T3 (da) Fremgangsmåder til oprensning af antistoffer
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
DK3305317T3 (da) Forbindelser til behandling af neuropsykiatriske forstyrrelser
EP2663266C0 (en) ENDOPROSTHESIS
DK3412687T3 (da) Fremgangsmåder til behandling af dlbcl
DK2635282T3 (da) Sammensætninger til behandling af myelofibrose
DK2785801T4 (da) Fremgangsmåde til formindskelse af isdannelse på et underlag
DK2785349T3 (da) Kombinationsbehandling af cancer
DK2526425T3 (da) Fremgangsmåde til diagnosticering af endometriel receptivitet
DK3246042T3 (da) Lægemiddelresistent immunterapi til behandling af cancer
BR112014013850A2 (pt) conjunto de prateleiras
DK3581199T3 (da) Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis
DK2715352T3 (da) Fremgangsmåde til vurdering af risiko for pml
DK2836460T3 (da) Fremgangsmåde til fremstilling af graphen
EP2725663A4 (en) CONNECTOR
EP2774585A4 (en) Stent
EP2668926A4 (en) STENT IMPLANT
DK3821891T3 (da) Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension
DK2516359T3 (da) Fremgangsmåde til fremstilling af ethylbenzen